

# Zanfina Ademi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2694087/zanfina-ademi-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122 papers	19,620 citations	19 h-index	132 g-index
132 ext. papers	25,750 ext. citations	6.6 avg, IF	5 L-index

#	Paper	IF	Citations
122	Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia.. <i>Pharmacoeconomics</i> , <b>2022</b> , 1	4.4	0
121	A Comparison of the Cost-Effectiveness of Lifestyle Interventions in Pregnancy.. <i>Value in Health</i> , <b>2022</b> , 25, 194-202	3.3	3
120	Population DNA screening for medically actionable disease risk in adults.. <i>Medical Journal of Australia</i> , <b>2022</b> ,	4	2
119	Lifetime impact of being underweight or overweight/obese during childhood in Vietnam.. <i>BMC Public Health</i> , <b>2022</b> , 22, 645	4.1	0
118	A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.. <i>Current Problems in Cardiology</i> , <b>2022</b> , 101211	17.1	1
117	Predictors of Stigma and Health-Related Quality of Life Among People Living with HIV in Northern Thailand.. <i>AIDS Patient Care and STDs</i> , <b>2022</b> , 36, 186-193	5.8	1
116	Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. <i>BMJ, The</i> , <b>2021</b> , 375, e068302	5.9	64
115	Attainment of low-density lipoprotein cholesterol goals in statin treated patients: real-world evidence from Australia. <i>Current Problems in Cardiology</i> , <b>2021</b> , 101068	17.1	2
114	Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	3
113	The Impact of Diabetes on Productivity in India. <i>Diabetes Care</i> , <b>2021</b> , 44, 2714-2722	14.6	0
112	The impact of coronary heart disease prevention on work productivity: a 10-year analysis. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> , 28, 418-425	3.9	3
111	Economic evaluation methods used in home-visiting interventions: A systematic search and review. <i>Health and Social Care in the Community</i> , <b>2021</b> , 29, 1650-1667	2.6	1
110	Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	3
109	First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis. <i>Current Problems in Cardiology</i> , <b>2021</b> , 100852	17.1	3
108	Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. <i>Internal Medicine Journal</i> , <b>2021</b> , 51, 769-779	1.6	0
107	Trends in the Utilization of Lipid-Lowering Medications in Australia: An Analysis of National Pharmacy Claims Data. <i>Current Problems in Cardiology</i> , <b>2021</b> , 100880	17.1	2
106	Estimating the Productivity Impact of Acute Myeloid Leukemia in Australia Between 2020 and 2029, Using a Novel Work Utility Measure: The Productivity-Adjusted Life Year (PALY). <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e1803-e1810	2.3	0

105	Switching, Persistence and Adherence to Statin Therapy: a Retrospective Cohort Study Using the Australian National Pharmacy Data. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 1	3.9	3
104	Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective. <i>American Journal of Preventive Cardiology</i> , <b>2021</b> , 6, 100151	1.9	0
103	The Health and Productivity Burden of Depression in South Korea. <i>Applied Health Economics and Health Policy</i> , <b>2021</b> , 19, 941-951	3.4	0
102	Chronic Kidney Disease and Cerebrovascular Disease: Consensus and Guidance From a KDIGO Controversies Conference. <i>Stroke</i> , <b>2021</b> , 52, e328-e346	6.7	6
101	Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , <b>2021</b> , 100, 35-48	9.9	8
100	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. <i>Heart Lung and Circulation</i> , <b>2021</b> , 30, 324-349	1.8	20
99	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , <b>2021</b> , 99, 34-47	9.9	42
98	Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. <i>Acta Diabetologica</i> , <b>2021</b> , 58, 39-46	3.9	2
97	Burden of disease and productivity impact of Streptococcus suis infection in Thailand. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0008985	4.8	3
96	The clinical utility of exome sequencing and extended bioinformatic analyses in adolescents and adults with a broad range of neurological phenotypes: an Australian perspective. <i>Journal of the Neurological Sciences</i> , <b>2021</b> , 420, 117260	3.2	4
95	Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden. <i>Pharmacoeconomics</i> , <b>2021</b> , 39, 271-273	4.4	6
94	The Preventable Productivity Burden of Kidney Disease in Australia. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> ,	12.7	1
93	Productivity burden of hypertension in Japan. <i>Hypertension Research</i> , <b>2021</b> , 44, 1524-1533	4.7	1
92	Cost Burden and Cost-Effective Analysis of the Nationwide Implementation of the Quality in Acute Stroke Care Protocol in Australia. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2021</b> , 30, 105931	2.8	4
91	Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus. <i>Endocrine Practice</i> , <b>2021</b> ,	3.2	1
90	Economic Evaluations of Child Nutrition Interventions in Low- and Middle-Income Countries: Systematic Review and Quality Appraisal. <i>Advances in Nutrition</i> , <b>2021</b> ,	10	1
89	Productivity Benefits of Preventing Type 2 Diabetes in Australia: A 10-Year Analysis. <i>Diabetes Care</i> , <b>2021</b> , 44, 715-721	14.6	0
88	Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2021</b> , 37, e3350	7.5	3

87	Prospective multisite cohort study of patient-reported outcomes in adults with new-onset seizures.. <i>Epilepsia Open</i> , <b>2021</b> ,	4	1
86	Natural Regression of Frailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis. <i>Gerontologist, The</i> , <b>2020</b> , 60, e286-e298	5	10
85	Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2982-3021	15.1	922
84	Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2020</b> , 22, 812-821	8.1	9
83	Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?. <i>Atherosclerosis</i> , <b>2020</b> , 304, 1-8	3.1	11
82	Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. <i>Pharmacoeconomics</i> , <b>2020</b> , 38, 1095-1113	4.4	11
81	Cost Effectiveness of Antenatal Lifestyle Interventions for Preventing Gestational Diabetes and Hypertensive Disease in Pregnancy. <i>Pharmacoeconomics - Open</i> , <b>2020</b> , 4, 499-510	2.1	10
80	The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487319896648	3.9	13
79	Assessing the impact of smoking on the health and productivity of the working-age Indonesian population using modelling. <i>BMJ Open</i> , <b>2020</b> , 10, e041832	3	1
78	Assessing the impact of smoking on the health and productivity of the working-age Indonesian population using modelling. <i>BMJ Open</i> , <b>2020</b> , 10, e041832	3	1
77	Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis. <i>Ecancermedicalscience</i> , <b>2020</b> , 14, 1047	2.7	16
76	Are Lifestyle Interventions to Reduce Excessive Gestational Weight Gain Cost Effective? A Systematic Review. <i>Current Diabetes Reports</i> , <b>2020</b> , 20, 6	5.6	7
75	Estimating the Productivity Burden of Pediatric Pneumococcal Disease in Thailand. <i>Applied Health Economics and Health Policy</i> , <b>2020</b> , 18, 579-587	3.4	4
74	Implementing a national first-line management program for moderate-severe knee osteoarthritis in Australia: A budget impact analysis focusing on knee replacement avoidance. <i>Osteoarthritis and Cartilage Open</i> , <b>2020</b> , 2, 100070	1.5	10
73	The cost-effectiveness of guideline-driven use of drug-eluting stents: propensity-score matched analysis of a seven-year multicentre experience. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 419-426	2.5	2
72	The Health and Productivity Burden of Migraines in Australia. <i>Headache</i> , <b>2020</b> , 60, 2291-2303	4.2	4
71	Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis. <i>Journal of Clinical Lipidology</i> , <b>2020</b> , 14, 772-783	4.9	9
70	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487320938272	3.9	15

69	The economic impact of familial hypercholesterolemia on productivity. <i>Journal of Clinical Lipidology</i> , <b>2020</b> , 14, 799-806.e3	4.9	3
68	Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , <b>2020</b> , 38, 1007-1020	4.4	8
67	The impact of diabetes on the productivity and economy of Bangladesh. <i>BMJ Global Health</i> , <b>2020</b> , 5,	6.6	10
66	Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling. <i>BMJ Open</i> , <b>2020</b> , 10, e039221	3	5
65	The costs of epilepsy in Australia: A productivity-based analysis. <i>Neurology</i> , <b>2020</b> , 95, e3221-e3231	6.5	9
64	Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden. <i>Pharmacoeconomics</i> , <b>2020</b> , 38, 747-764	4.4	4
63	Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study. <i>Advances in Therapy</i> , <b>2019</b> , 36, 3265-3278	4.1	6
62	Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 2047487319878953	3.9	7
61	The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. <i>International Journal of Cardiology</i> , <b>2019</b> , 285, 1-5	3.2	9
60	Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. <i>Pharmacoeconomics</i> , <b>2019</b> , 37, 1277-1286	4.4	6
59	The impact of diabetes on productivity in China. <i>Diabetologia</i> , <b>2019</b> , 62, 1195-1203	10.3	19
58	Productivity Burden of Hypertension in Australia. <i>Hypertension</i> , <b>2019</b> , 73, 777-784	8.5	30
57	First seizure presentations in adults: beyond assessment and treatment. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 1039-1045	5.5	3
56	Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study". <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 287-300	4.9	18
55	Prevalence and Outcomes of Undiagnosed Peripheral Arterial Disease Among High Risk Patients in Australia: An Australian REACH Sub-Study. <i>Heart Lung and Circulation</i> , <b>2019</b> , 28, 939-945	1.8	4
54	Global Incidence of Frailty and Prefrailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , <b>2019</b> , 2, e198398	10.4	119
53	Prevalence and impact of non-cardiovascular comorbidities among older adults hospitalized for non-ST segment elevation acute coronary syndrome. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2019</b> , 9, 250-261	3.6	11
52	Economic evaluation of a novel genetic screening test for risk of venous thromboembolism compared with standard of care in women considering combined hormonal contraception in Switzerland. <i>BMJ Open</i> , <b>2019</b> , 9, e031325	3	1

51	Comparisons of direct and indirect utilities in adult epilepsy populations: A systematic review. <i>Epilepsia</i> , <b>2019</b> , 60, 2466-2476	6.4	0
50	Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 858-868	3.9	10
49	The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience. <i>Applied Health Economics and Health Policy</i> , <b>2018</b> , 16, 661-674	3.4	6
48	Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201985	3.7	2
47	Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight. <i>Swiss Medical Weekly</i> , <b>2018</b> , 148, w14626	3.1	14
46	Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop. <i>Public Health Genomics</i> , <b>2018</b> , 21, 121-132	1.9	6
45	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 1859-1922	4.0	1283
44	Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. <i>International Journal of Cardiology</i> , <b>2018</b> , 270, 54-59	3.2	14
43	Herpes zoster vaccine: A health economic evaluation for Switzerland. <i>Human Vaccines and Immunotherapeutics</i> , <b>2017</b> , 13, 1495-1504	4.4	11
42	A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 44, 494-506	5.1	5
41	Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective. <i>Applied Health Economics and Health Policy</i> , <b>2017</b> , 15, 363-374	3.4	1
40	Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction. <i>Swiss Medical Weekly</i> , <b>2017</b> , 147, w14533	3.1	16
39	Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3531	1.8	9
38	A systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for the treatment of multivessel coronary artery disease in the drug-eluting stent era. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2016</b> , 2, 261-270	4.6	11
37	Cost-effectiveness of primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation from the Swiss perspective. <i>Swiss Medical Weekly</i> , <b>2016</b> , 146, w14382	3.1	5
36	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1459-1544	4.0	3525
35	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1545-1602	4.0	3801
34	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1659-1724	4.0	2431

33	Rate of change in renal function and mortality in elderly treated hypertensive patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2015</b> , 10, 1154-61	6.9	12
32	Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity. <i>Medicine (United States)</i> , <b>2015</b> , 94, e590	1.8	7
31	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. <i>Lancet, The</i> , <b>2015</b> , 386, 2145-91	40	1203
30	Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland. <i>Pharmacoeconomics</i> , <b>2015</b> , 33, 1311-24	4.4	6
29	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , <b>2015</b> , 386, 743-800	40	3802
28	Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia. <i>European Journal of Preventive Cardiology</i> , <b>2015</b> , 22, 344-53	3.9	12
27	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , <b>2014</b> , 384, 957-79	40	497
26	Prolonged effectiveness of coronary artery bypass surgery versus drug-eluting stents in diabetics with multi-vessel disease: an updated systematic review and meta-analysis. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 346-53	3.2	13
25	Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms. <i>European Journal of Preventive Cardiology</i> , <b>2014</b> , 21, 384-90	3.9	12
24	Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , <b>2014</b> , 8, 390-400	4.9	105
23	Using WOMAC Index scores and personal characteristics to estimate Assessment of Quality of Life utility scores in people with hip and knee joint disease. <i>Quality of Life Research</i> , <b>2014</b> , 23, 2365-74	3.7	12
22	Cost effectiveness of eplerenone in patients with chronic heart failure. <i>American Journal of Cardiovascular Drugs</i> , <b>2014</b> , 14, 209-16	4	11
21	Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , <b>2014</b> , 384, 980-1004	40	950
20	Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 77, 116-21	3.8	32
19	Performance of the assessment of quality of life measure in people with hip and knee joint disease and implications for research and clinical use. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 481-8	4.7	12
18	Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study. <i>American Journal of Hypertension</i> , <b>2014</b> , 27, 199-206	2.3	16
17	Quantifying the excess cost and resource utilisation for patients with complications associated with elective knee arthroscopy: a retrospective cohort study. <i>Knee</i> , <b>2014</b> , 21, 491-6	2.6	16
16	Predictors of health care use among patients with or at high risk of atherothrombotic disease: two-year follow-up data. <i>International Journal of Cardiology</i> , <b>2014</b> , 175, 72-7	3.2	5

15	Diabetes prevention and treatment strategies: are we doing enough?. <i>Diabetes Care</i> , <b>2013</b> , 36, 2714-9	14.6	17
14	Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis. <i>American Journal of Cardiovascular Drugs</i> , <b>2013</b> , 13, 121-8	4	5
13	The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registry. <i>Cardiovascular Therapeutics</i> , <b>2013</b> , 31, 370-6	3.3	2
12	Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort. <i>Cardiovascular Therapeutics</i> , <b>2013</b> , 31, 45-52	3.3	8
11	Outcomes and excess costs among patients with cardiovascular disease. <i>Heart Lung and Circulation</i> , <b>2013</b> , 22, 724-30	1.8	7
10	Cardiovascular readmissions and excess costs following percutaneous coronary intervention in patients with chronic kidney disease: data from a large multi-centre Australian registry. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 2783-90	3.2	10
9	A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 2391-6	3.2	44
8	Comparison of health-related quality of life, work status, and health care utilization and costs according to hip and knee joint disease severity: a national Australian study. <i>Physical Therapy</i> , <b>2013</b> , 93, 889-99	3.3	37
7	Overview of pharmacoeconomic modelling methods. <i>British Journal of Clinical Pharmacology</i> , <b>2013</b> , 75, 944-50	3.8	26
6	Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. <i>Medical Journal of Australia</i> , <b>2012</b> , 196, 193-7	4	13
5	Predictors of increasing waist circumference in an Australian population. <i>Public Health Nutrition</i> , <b>2011</b> , 14, 870-81	3.3	8
4	Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 1456-65	3.5	5
3	Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry. <i>American Journal of Cardiovascular Drugs</i> , <b>2010</b> , 10, 85-94	4	12
2	The economic implications of treating atherothrombotic disease in Australia, from the government perspective. <i>Clinical Therapeutics</i> , <b>2010</b> , 32, 119-32; discussion 106-7	3.5	14
1	Drug treatment and cost of cardiovascular disease in Australia. <i>Cardiovascular Therapeutics</i> , <b>2009</b> , 27, 164-72	3.3	13